{"id":"W4387811021","doi":"10.1016/j.annonc.2023.09.2263","title":"1129P Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck","keywords":"Medicine; Internal medicine; Ipilimumab; Oncology; Interim analysis; Proportional hazards model; Vemurafenib; Dacarbazine; Adjuvant therapy; Progression-free survival; Censoring (clinical trials); Hazard ratio; Survival analysis; Melanoma; Randomized controlled trial; Overall survival; Immunotherapy; Metastatic melanoma; Cancer; Chemotherapy; Confidence interval; Pathology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001613311,0.001190833,0.002968566,0.000274778,0.0004175818,0.001213018,0.0007350834,0.001500603,0.004512022],"category_scores_gemma":[0.001350008,0.0005702776,0.002192046,0.0004304471,0.0009782829,0.0009727834,0.0003596482,0.004240775,0.0007309863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008070283,"about_ca_system_score_gemma":0.0009334022,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001350107,"about_ca_topic_score_gemma":0.00291227,"domain_scores_codex":[0.9993644,0.0003007697,0.00002804472,0.00012528,0.00004386415,0.0001377025],"domain_scores_gemma":[0.9991584,0.0002338764,0.0001676083,0.00008589723,0.00005346231,0.0003008272],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9670122,0.003720841,0.00197897,0.0002350186,0.001608786,0.00004013062,0.00003071949,0.0006739121,0.003545244,0.00007606758,0.000861045,0.02021708],"study_design_scores_gemma":[0.8016812,0.1800014,0.01297469,0.00004474811,0.0020126,0.00008015174,0.00003757998,0.00094895,0.0008900439,0.0002157314,0.001080816,0.00003219245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944822,0.002334403,0.0002720823,0.0005355389,0.0003219201,0.000402394,0.0006789715,0.00004673346,0.0009259444],"genre_scores_gemma":[0.993605,0.001331772,0.0004069684,0.0006207436,0.0002531403,0.0006325269,0.001041851,0.00002245002,0.002085638],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004512022,"threshold_uncertainty_score":0.01509416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06770739859690496,"score_gpt":0.3766595135407216,"score_spread":0.3089521149438167,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}